NEW YORK, NY / ACCESS Newswire / January 22, 2025 / Pomerantz LLP is investigating claims on behalf of investors of IGM Biosciences, Inc. ("IGM" or the "Company") (NASDAQ:IGMS). Such investors are ...

Steven Weber, the Principal Accounting Officer at IGM Biosciences, Inc. (NASDAQ:IGMS), recently sold shares of the company's common stock. The transaction comes as the stock has experienced ...

IGM Biosciences is laying off 100 workers as it shuts down two research projects, causing the Mountain View company's stock ...

Fintel reports that on January 13, 2025, JP Morgan upgraded their outlook for IGM Biosciences (NasdaqGS:IGMS) from ...

IGM Biosciences Inc (IGMS) stock saw a modest uptick, ending the day at $2 which represents a slight increase of $0.29 or 16.96% from the prior close of $1.71. The stock opened at $1.75 and touched a ...

Bank of America Securities analyst Charlie CY Yang maintained a Hold rating on IGM Biosciences (IGMS – Research Report) today. The company’s ...

Wedbush restated their neutral rating on shares of IGM Biosciences (NASDAQ:IGMS – Free Report) in a report issued on Friday ...

IGM Biosciences (NASDAQ:IGMS – Get Free Report) had its target price reduced by research analysts at Truist Financial from ...

IGM Biosciences, Inc. operates as a biotechnology company, which develops antibodies for the treatment of cancer. It offers the IgM platform to expand upon the inherent properties of IgM ...

IGM Biosciences has halted all oncology programs and faces a significant pipeline upheaval, leading to a greater-than-50% drop in share price. Despite holding substantial liquid assets and a ...